Drugs / Mosapride
Mosapride
also known as
mosapride citrate · GASMOTIN · AS-4370 · GR107719B · Mosaprida · Mosapride Citrate Tablets · Mosart · Rimopride citrate · +1 more
Small molecule targets HTR4 via activation
Trials 14
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02201316 | Feb → Mar 2014 | gastritis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT02106130 | May → Jun 2013 | — | IlDong Pharmaceutical Co Ltd | Completed | No outcome recorded |
| Phase 22 trials · 1 met primary | ||||||
| Phase 2 | NCT06782594 | Oct 2024 → Jun 2025 overdue | intestinal dysmotility syndrome | Shandong New Time Pharmaceutical Co., LTD | Recruiting | No outcome recorded |
| Phase 2 | NCT01505777 | May 2011 → Jun 2012 | irritable bowel syndrome | Hanmi Pharmaceutical Company Limited | Completed | Met primary |
| Phase 33 trials | ||||||
| Phase 3 | NCT03477266 | Apr → Jun 2018 | ileus | Benha University | Completed | No outcome recorded |
| Phase 3 | NCT03225248 | Nov 2014 → Sep 2015 | dyspepsia | Korea United Pharm. Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00742872 | Sep 2008 → Jun 2010 | irritable bowel syndrome | American University of Beirut Medical Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 43 trials | ||||||
| Phase 4 | NCT02433847 | May 2015 → Apr 2016 | constipation disorder, irritable bowel syndrome | Seoul National University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02264587 | Oct 2014 → Sep 2015 | gastroparesis | Liangzhou Wei | Unknown | No outcome recorded |
| Phase 4 | NCT02180334 | Jul → Nov 2014 | type 2 diabetes mellitus | Seoul National University Hospital | Completed | No outcome recorded |
| Phase not applicable4 trials | ||||||
| — | NCT06481371 | Jun 2024 → Feb 2025 | depressive disorder, dyspepsia | Nanjing First Hospital, Nanjing Medical University | Unknown | No outcome recorded |
| — | NCT04493125 | Jul 2020 → Mar 2021 | gastric cancer | Gangnam Severance Hospital | Completed | No outcome recorded |
| — | NCT02982668 | Jan 2017 → Dec 2020 | stroke disorder | Xijing Hospital | Terminated | No outcome recorded |
| — | NCT02984930 | Dec 2016 → Jul 2018 | gastroesophageal reflux disease | Gangnam Severance Hospital | Unknown | No outcome recorded |
| Comparator or background therapy22 trials | ||||||
| Phase 1 | NCT01781897 Comparator | Feb 2013 → Dec 2015 | constipation disorder | Huazhong University of Science and Technology | Unknown | No outcome recorded |
| Phase 1 | NCT01274793 Comparator | Nov 2010 → Dec 2015 | constipation disorder, functional diarrhea | Huazhong University of Science and Technology | Unknown | No outcome recorded |
| Phase 1/2 | NCT05720442 Background | Feb 2023 → Jan 2025 | intestinal dysmotility syndrome | Guang'anmen Hospital of China Academy of Chinese Medical Sciences | Unknown | No outcome recorded |
| Phase 1/2 | NCT03149393 Comparator | Feb 2017 → Dec 2020 | dyspepsia | Xiyuan Hospital of China Academy of Chinese Medical Sciences | Unknown | No outcome recorded |
| Phase 3 | NCT06826443 Comparator | Feb → May 2025 overdue | — | Ain Shams University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT03184402 Comparator | Apr → Jul 2017 | dyspepsia | Daewoong Pharmaceutical Co. LTD. | Completed | No outcome recorded |
| Phase 3 | NCT03024086 Comparator | Dec 2016 → Apr 2017 | dyspepsia | Daewoong Pharmaceutical Co. LTD. | Completed | No outcome recorded |
| Phase 3 | NCT02831543 Comparator | Apr 2016 → Jan 2017 | dyspepsia | IlDong Pharmaceutical Co Ltd | Unknown | No outcome recorded |
| Phase 3 | NCT01411501 Comparator | Sep 2011 → Oct 2014 | constipation disorder | Guang'anmen Hospital of China Academy of Chinese Medical Sciences | Completed | No outcome recorded |
| Phase 3 | NCT01284764 Comparator | Jan → Jul 2011 | — | Inje University | Completed | No outcome recorded |
| Phase 4 | NCT02606617 Comparator | Dec 2015 → Sep 2016 | type 2 diabetes mellitus | Third Military Medical University | Unknown | No outcome recorded |
| Phase 4 | NCT02056405 Comparator | Dec 2015 → Dec 2016 | ileus | Hospital Italiano de Buenos Aires | Unknown | No outcome recorded |
| Phase 4 | NCT02887573 Background | Jan 2014 → Jul 2017 | polyp | Kaichun Wu | Unknown | No outcome recorded |
| Phase 4 | NCT00729339 Comparator | Jun 2008 → Apr 2009 | gastroesophageal reflux disease | Lotung Poh-Ai Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00663897 Comparator | May 2008 → Jul 2009 | dyspepsia | Lotung Poh-Ai Hospital | Completed | Missed primary |
| — | NCT07607249 Comparator | Mar 2026 → Mar 2027 expected | digestive system disorder | Zhenyu Zhang | Enrolling by invitation | No outcome recorded |
| — | NCT07096921 Background | Jul 2025 → Mar 2026 overdue | dyspepsia | Eunpyeong St. Mary's Hospital | Active not recruiting | No outcome recorded |
| — | NCT06156995 Comparator | Jan → Dec 2023 | constipation disorder | Guoliang Wu | Unknown | No outcome recorded |
| — | NCT05966246 Comparator | Jan 2022 → Jun 2023 | gastric cancer | Gangnam Severance Hospital | Completed | No outcome recorded |
| — | NCT04905147 Comparator | Jul 2021 → Jul 2023 | colorectal cancer, ileus | Mahidol University | Unknown | No outcome recorded |
| — | NCT04350346 Comparator | Mar 2020 → Sep 2021 | gallstones | Yonsei University | Unknown | No outcome recorded |
| — | NCT03040817 Comparator | Sep 2017 → Aug 2019 | — | Zhongda Hospital | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2016-08-31 | Korea United Pharm. Inc. | Results 유나이티드제약 ‘가스티인CR정 런칭 심포지엄’ 성료 kup.co.kr ↗ |
| 2016-07-06 | Korea United Pharm. Inc. | Regulatory 한국유나이티드제약, 기능성 소화불량 개량신약 ‘가스티인CR정’ 허가 kup.co.kr ↗
한국유나이티드제약(대표 강덕영)이 식품의약품안전처로부터 기능성 소화불량 개량신약인 ‘가스티인CR정’의 허가를 획득했다. |
| 2009-04-22 | Sumitomo Pharma America, Inc. | Regulatory Acquisition of an additional indication relating to pretreatment for barium enema X-ray examination by concomitant use of NIFLEC and GASMOTIN sumitomo-pharma.com ↗
Ajinomoto Co., Inc. (Headquarters: Tokyo, Japan; President: Norio Yamaguchi; hereinafter called "Ajinomoto") and Dainippon Sumitomo Pharma Co., Ltd. (Headquarters: Osaka, Japan; President: Masayo Tada; hereinafter called "DSP") have obtained an approval for an additional indication and new dosing regimen relating to pretreatment for barium enema X-ray examination by concomitant use of NIFLEC ® and GASMOTIN ® (GASMOTIN ® Tablets 2.5mg, GASMOTIN ® Tablets 5mg, and GASMOTIN ® Powder) in Japan as of April 22, 2009. |
| 2009-03-16 | Sumitomo Pharma America, Inc. | Regulatory Launch of "PRONAMID",a gastro-prokinetic agent for dogs sumitomo-pharma.com ↗
Dainippon Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; President: Masayo Tada) launches PRONAMID ® tablets, a gastro-prokinetic agent for dogs (generic name: mosapride citrate hydrate) on March 18, 2009, after obtaining a manufacturing and marketing approval as of February 3, 2009. |
| 2007-05-15 | Eisai Inc. | Regulatory Eisai Submits Application for Gastroprokinetic Agent Gasmotin® in Thailand eisai.com ↗ |
All press releases naming this drug 6 releases
| Date | Issuer | Release |
|---|---|---|
| 2016-08-31 | Korea United Pharm. Inc. | 유나이티드제약 ‘가스티인CR정 런칭 심포지엄’ 성료 kup.co.kr ↗ |
| 2016-07-06 | Korea United Pharm. Inc. | 한국유나이티드제약, 기능성 소화불량 개량신약 ‘가스티인CR정’ 허가 kup.co.kr ↗ |
| 2011-07-04 | Daewoong Pharmaceutical Co. LTD. | Gasmotin powder for functional dyspepsia daewoong.co.kr ↗ |
| 2009-04-22 | Sumitomo Pharma America, Inc. | Acquisition of an additional indication relating to pretreatment for barium enema X-ray examination by concomitant use of NIFLEC and GASMOTIN sumitomo-pharma.com ↗ |
| 2009-03-16 | Sumitomo Pharma America, Inc. | Launch of "PRONAMID",a gastro-prokinetic agent for dogs sumitomo-pharma.com ↗ |
| 2007-05-15 | Eisai Inc. | Eisai Submits Application for Gastroprokinetic Agent Gasmotin® in Thailand eisai.com ↗ |
Evidence & citations 14 cited values
Every value below carries the sentence it was read from. 37 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mosapride | “This study is a multi-center, randomized, active-controlled, double-blind, non-inferiority, phase III clinical trial evaluating efficacy and safety of once-daily mosapride...” NCT03225248 ↗27“mosapride is a selective serotonin-4 (5-HT4) receptor agonist with gastrointestinal stimulating activity, contracting smooth muscle” NCT04350346 ↗ “Mosapride citrate, a selective 5-HT4 receptor agonist, stimulates gastrointestinal motility.” PMID 25809913 ↗ Mar 2015 |
| Known as | AS-4370 | ChEMBL registry synonym — accepted as the source's own label CHEMBL60889 ↗ |
| Known as | GASMOTIN | “This study aims to determine the relative bioavailability of two candidate formulations of mosapride citrate 5mg tablets compared the reference product GASMOTIN (mosapride...” NCT02201316 ↗3“Esomeprazole(Hanxium®) 40 mg once daily and mosapride (Gasmotin®) 5 mg t.i.d for 4 weeks.” NCT02984930 ↗ |
| Known as | GR107719B | “This study is required to select a candidate mosapride citrate (GR107719B) formulation for further development and provide data to allow the design of a future pivotal...” NCT02201316 ↗ |
| Known as | Mosaprida | ChEMBL registry synonym — accepted as the source's own label CHEMBL60889 ↗ |
| Known as | mosapride citrate | “This study aims to determine the relative bioavailability of two candidate formulations of mosapride citrate 5mg tablets compared the reference product GASMOTIN (mosapride...” NCT02201316 ↗9“Among them, mosapride citrate is widely used as a representative drug, as it is a 5-hydroxytryptamine 4 receptor agonist that increases gastrointestinal motility.” NCT05966246 ↗ “Mosapride citrate, a selective 5-HT4 receptor agonist, stimulates gastrointestinal motility.” PMID 25809913 ↗ Mar 2015 “mosapride citrate tablets” NCT07607249 ↗ |
| Known as | Mosapride Citrate Tablets | “Each participant receive Esomeprazole （Nexium） 40mg bid + Mosapride （Mosapride Citrate Tablets） 5mg tid.” NCT03040817 ↗ |
| Known as | Mosart | ChEMBL registry synonym — accepted as the source's own label CHEMBL60889 ↗ |
| Known as | Rimopride citrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL60889 ↗ |
| Known as | UI05MSP015CT | “This study is a multi-center, randomized, active-controlled, double-blind, non-inferiority, phase III clinical trial evaluating efficacy and safety of once-daily mosapride...” NCT03225248 ↗ |
| Action | Activate | “Mosapride citrate, a selective 5-HT4 receptor agonist, stimulates gastrointestinal motility.” PMID 25809913 ↗ Mar 20151“Serotonin 4 (5-HT4) receptor agonist” CHEMBL60889 ↗ |
| Modality | Small molecule | — CHEMBL60889 ↗ |
| Route | Oral | “taken orally” NCT00742872 ↗ |
| Target | HTR4 | “Serotonin 4 (5-HT4) receptor agonist” CHEMBL60889 ↗ |